This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineTisotumab vedotin
an investigational antibody–drug conjugate directed to tissue factor
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
innovaTV 301: Recurrent or metastatic cervical cancer
-
Phase 1
-
Phase 2
-
Phase 3
innovaTV 205: Recurrent or metastatic cervical cancer
-
Phase 1
-
Phase 2
-
Phase 3
innovaTV 207: Advanced solid tumors
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources

High-level synopsis of tisotumab vedotin and ongoing clinical trials

Detailed information about tisotumab vedotin clinical trials
Related Videos
Tisotumab Vedotin Proposed Mechanism of Action